سعر بيبتازول 30مجم كبسولات 2023

Lansoprazole 30 mg enteric-coated (delayed-release) capsules, proton pump inhibitor for peptic ulcer, GERD and H. pylori eradication regimens. Pack of 14 capsules.

• Short-term treatment of active duodenal ulcer and benign gastric ulcerPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Treatment of symptomatic GERD and short-term treatment of erosive esophagitisPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• H. pylori eradication (triple therapy with amoxicillin and clarithromycin) to reduce the risk of duodenal ulcer recurrencePopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to any component; co-administration with rilpivirine-containing products.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Symptomatic response does not exclude gastric malignancy; acute tubulointerstitial nephritis; Clostridioides difficile-associated diarrhoea; bone fracture with long-term/high-dose use; severe cutaneous adverse reactions.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• RilpivirineContraindicated: reduced rilpivirine exposure.DailyMed (U.S. National Library of Medicine)
• SucralfateDelayed and reduced lansoprazole absorption; take lansoprazole at least 30 minutes before sucralfate.DailyMed (U.S. National Library of Medicine)

• Published observational studies overall do not indicate an association of adverse pregnancy outcomes with lansoprazole; animal data at 6.4x MRHD showed reduced bone parameters in offspring.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No information on presence in human milk; present in rat milk. Weigh benefits of breastfeeding against maternal need.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Lansoprazole: Substituted benzimidazole that suppresses gastric acid secretion by specific inhibition of the (H+, K+)-ATPase enzyme system (proton pump) at the secretory surface of the gastric parietal cell, blocking the final step of acid production (US Prevacid label).